APG Asset Management N.V. Buys New Stake in BioNTech SE (NASDAQ:BNTX)

APG Asset Management N.V. purchased a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 46,900 shares of the company's stock, valued at approximately $5,161,000.

A number of other institutional investors have also recently bought and sold shares of BNTX. SG Americas Securities LLC increased its position in shares of BioNTech by 412.3% in the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock worth $4,726,000 after acquiring an additional 33,375 shares in the last quarter. Mirabaud & Cie SA acquired a new position in BioNTech in the 4th quarter worth approximately $684,000. Bank of New York Mellon Corp grew its position in BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after purchasing an additional 150 shares in the last quarter. Vestcor Inc acquired a new stake in BioNTech during the 3rd quarter valued at $784,000. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of BioNTech in the fourth quarter valued at $1,118,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on BNTX. Citigroup began coverage on BioNTech in a research report on Thursday, March 13th. They set a "buy" rating and a $145.00 price objective for the company. Morgan Stanley dropped their price objective on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. HC Wainwright lowered their price target on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Truist Financial started coverage on BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 target price on the stock. Finally, Canaccord Genuity Group restated a "buy" rating and set a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $143.44.

Remove Ads

BioNTech Stock Performance

BNTX stock traded down $0.75 during trading on Wednesday, reaching $98.25. 614,051 shares of the stock were exchanged, compared to its average volume of 859,179. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $23.58 billion, a P/E ratio of -46.79 and a beta of 1.07. The stock has a 50 day simple moving average of $103.82 and a 200-day simple moving average of $111.43.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech's revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.90 EPS. As a group, sell-side analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.